| Literature DB >> 27300429 |
Pierre Bruhns1, Jean-Luc Teillaud2.
Abstract
In this issue of Cancer Cell, Dahan and colleagues demonstrate that modified Fc regions of agonistic anti-human CD40 mAbs can drastically increase their efficiency in a mouse pre-clinical model expressing human CD40 and IgG receptors. This study also highlights the fine balance between increased treatment efficacy and secondary side effects.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27300429 DOI： 10.1016/j.ccell.2016.05.009
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743